First Manhattan’s Avadel Pharmaceuticals AVDL Stock Holding History

First Manhattan’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-100	Closed	-$1.69K	–	710
2024 Q1	$1.69K	Buy	+100	New	+$1.49K	﹤0.01%	1295

Other funds holding AVDL

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Manhattan's AVDL Position: Q2 2024 in Review

First Manhattan sold out of Avadel Pharmaceuticals (AVDL) in Q2 2024, closing a stake of 100 shares — an estimated $1.69K sold.

First Manhattan first reported a position in AVDL in Q1 2024 and held it in 1 quarter. The position peaked at $1.69K in Q1 2024. 155 funds tracked by Wall St. Rank hold AVDL as of Q2 2024.

First Manhattan reported no remaining Avadel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 100 Avadel Pharmaceuticals shares in Q2 2024, an estimated $1.69K.
First Manhattan first reported a position in Avadel Pharmaceuticals in Q1 2024 and held it in 1 quarter.
First Manhattan's Avadel Pharmaceuticals position peaked at $1.69K in Q1 2024.
155 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.